These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1272 related items for PubMed ID: 16645966
1. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S. Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966 [Abstract] [Full Text] [Related]
2. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis. Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T. J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070 [Abstract] [Full Text] [Related]
3. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults. Huang WF, Hsiao FY, Wen YW, Tsai YW. Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003 [Abstract] [Full Text] [Related]
10. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice. Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC. Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789 [Abstract] [Full Text] [Related]
11. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs. Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S. Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799 [Abstract] [Full Text] [Related]
14. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rahme E, Nedjar H. Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138 [Abstract] [Full Text] [Related]
18. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT. Arch Intern Med; 2005 May 09; 165(9):978-84. PubMed ID: 15883235 [Abstract] [Full Text] [Related]
19. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Andersohn F, Suissa S, Garbe E. Circulation; 2006 Apr 25; 113(16):1950-7. PubMed ID: 16618816 [Abstract] [Full Text] [Related]
20. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J. Pharmacoepidemiol Drug Saf; 2007 May 25; 16(5):493-503. PubMed ID: 17086567 [Abstract] [Full Text] [Related] Page: [Next] [New Search]